Gilead Sciences stock trades at EUR 134.95 with a minus 56.7 P/ E

Published on 10/09/2026 at 20:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock stood at EUR 134.95 on October 9, 2026, above EUR 131.21. Market value reached USD 186.9 billion and P/E was minus 56.7.

Key points in brief

Gilead Sciences stock was trading at EUR 134.95 at Lang & Schwarz on October 9, 2026, up 2.85 percent versus EUR 131.21.
The Nasdaq quote was USD 150.71, while the 52-week range was USD 114.02 to USD 157.29.
Market capitalization was USD 186.9 billion and the reported P/E was minus 56.7.

Pop-Art-Comic Gilead Sciences Forscher hält leuchtendes Reagenzglas im Biopharma-Labor — Gilead Sciences Pop-Art-Comic ISIN US3755581036 Wissenschaftler hält leuchtendes Reagenzglas Halbton Laborentdeckung bunt, Illustration mit AI erstellt.

Gilead Sciences (ISIN US3755581036) was trading at EUR 134.95 at Lang & Schwarz at 8:16 p.m. CEST on October 9, 2026, up 2.85 percent versus the prior close of EUR 131.21. The after-hours quote places the stock close to its recent US trading range, but the euro price remains the key reference for investors in Germany.

Bid ask and Nasdaq price

The Lang & Schwarz bid was EUR 134.88 and the ask was EUR 135.02 at the same timestamp. On the Nasdaq, Gilead Sciences was trading at USD 150.71 at 2:17 p.m. EDT on October 9, 2026, with the US session open.

The US quote was USD 3.61 above its prior close of USD 147.10, a gain of 2.45 percent in that market. The difference between the euro and US quotations reflects venue and currency rather than two separate moves in the same instrument.

Range and valuation

Gilead Sciences had a 52-week range of USD 114.02 to USD 157.29 on October 9, 2026. At USD 150.71, the Nasdaq price was 4.18 percent below the 52-week high, leaving the range position more informative than the daily move alone.

Market capitalization stood at USD 186.9 billion, while the reported P/E was minus 56.66 on October 9, 2026. The negative ratio reflects the earnings denominator in the quoted valuation data and should not be read as a positive earnings multiple.

Comparison with peers

Gilead Sciences: plus 2.85 percent, P/E minus 56.7, market capitalization USD 186.9 billion

AbbVie (NYSE, USD): plus 1.59 percent, P/E 77.97, market capitalization USD 489.0 billion

Vertex Pharmaceuticals (NASDAQ, USD): plus 1.33 percent, P/E 29.70, market capitalization USD 129.4 billion

Analyst target and price

Gekko listed a consensus 12-month target of USD 158.65 on September 30, 2026, based on 17 Buy ratings and four Hold ratings. That target was 5.27 percent above the USD 150.71 Nasdaq price cited in the same market context.

MarketBeat reported on October 8, 2026 that Royal Bank of Canada raised its target from USD 123.00 to USD 126.00 while maintaining a sector perform rating. The target changes illustrate the dispersion between individual analyst views and the broader consensus.

Price remains the market marker

For German investors, the relevant closing reference remains EUR 131.21 at Lang & Schwarz, while the latest after-hours quote was EUR 134.95. The US listing adds context through its USD 150.71 price, 52-week range and USD 186.9 billion market value.

The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.